SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001558370-23-018568
Filing Date
2023-11-09
Accepted
2023-11-09 16:08:13
Documents
15
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A xlo-20230331x10qa.htm   iXBRL 10-Q/A 52798
2 EX-31.1 xlo-20230331xex31d1.htm EX-31.1 16926
3 EX-31.2 xlo-20230331xex31d2.htm EX-31.2 16926
  Complete submission text file 0001558370-23-018568.txt   290494

Data Files

Seq Description Document Type Size
4 EX-101.SCH xlo-20230331.xsd EX-101.SCH 4313
5 EX-101.DEF xlo-20230331_def.xml EX-101.DEF 35450
6 EX-101.LAB xlo-20230331_lab.xml EX-101.LAB 21145
7 EX-101.PRE xlo-20230331_pre.xml EX-101.PRE 13634
9 EXTRACTED XBRL INSTANCE DOCUMENT xlo-20230331x10qa_htm.xml XML 6757
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

IRS No.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-40925 | Film No.: 231392404
SIC: 2834 Pharmaceutical Preparations